Global Tissue Diagnostics Market is expected to grow at a Healthy Rate of 7% by 2026 - A Robust Tool which defines a New Era for Cancer Diagnosis and Treatments

Tissue is defined as a group of cells or fluids that possess similar structures and function together to perform a specific job in the body. A tissue diagnosis is the diagnosis made when a piece of tissue is examined by a pathologist, to diagnose diseases based on tissues from organs and tumors.

Growing Adoption of Tissue Diagnostics for Early Detection & Screening of Cancer

Tissue-based diagnostic testing continues to serve as one of the gold standards for cancer diagnosis. No other technology can capture the disease's biological context and the critical parameters that factor into patient outcomes. From a biopsy, a pathologist can determine the type of cancer, the stage, and the degree to which cancer has invaded healthy tissue. Tissue diagnosis is considered an efficient method for the clinical diagnosis of these diseases. The increased adoption of tissue diagnosis to understand the causes of cancer, identify targets for treatments, and discover biomarkers is expected to boost its demand in the coming years.

The rising prevalence of cancer and neoplastic cases, growing demand for personalized medicines, developing infrastructure for cancer diagnosis, technological advancement in tissue diagnostics, rising developments in consumables & instruments used in tissue diagnosis, and increasing demand for oncology screening are some of the key factors driving the growth of global tissue diagnostics market.

Technological Advancements in Digital Pathology Fuels the Demand of Tissue Diagnostics Market

Digital pathology can help reduce human error as well as produce precise diagnostic results in a short turnaround time. The processes involved in digital pathology allow to speed up routine tasks without reducing the quality of the execution of each task. For instance,

In June 2022, Roche announced the launch of its next-generation VENTANA DP 600 slide scanner. This slide scanner produces excellent image quality of stained histology slides from patient tissue samples.

In May 2022, Leica Biosystems announced the launch of its compact, dual-retort tissue processor, the HistoCore PEGASUS Plus.

Usage of Immunohistochemistry (IHC) Technology in Cancer Biomarker Research

IHC is a hugely popular tool used in cancer research. Different types of cancer are associated with specific protein biomarkers that can be identified via IHC that serve as a powerful tool to investigate tumor development and responses. Using these techniques, researchers can identify the histogenesis of tumors, and stage tumors, predict tumor prognosis, and predict and monitor therapeutic response.

North America Holds Major Market Share But APAC Expected to Witness Strong Growth

From a geographical perspective, North America currently holds a major share in the global tissue diagnostics market. North America is expected to continue to hold a major share in the coming years due to the growing prevalence of cancer, growing adoption of technologically advanced equipment and consumables, favorable reimbursement policies, and increasing awareness campaigns to minimize cancer incidence in the region.

Competitive Landscape Analysis: Tissue Diagnostics Market

Some of the key players operating in the global tissue diagnostics market are Abbott Laboratories, F.Hoffmann-LA Roche Ltd, Danaher, Thermo Fisher Scientific, Agilent Technologies Inc., and Merck KGaA, among others.

Growth Strategies Adopted by Market Players to Establish Their Strong Foothold in the Tissue Diagnostics Market

Players operating in the tissue diagnostics market are adopting organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share. For instance,

In February 2022, Labcorp announced the acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

In October 2021, Roche announced the launch of its AVENIO Tumor Tissue CGP Kit. The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house.

Explore Detailed Insights on Tissue Diagnostics Market Research Report with TOC @ https://meditechinsights.com/tissue-diagnostics-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.